Literature DB >> 7211951

Frequency of new mutants among boys with Duchenne muscular dystrophy.

K Bucher, V Ionasescu, J Hanson.   

Abstract

Haldane's rule states that one-third of the cases of an X-linked recessive lethal should represent new mutations. This rule is derived under the assumptions that there is equilibrium between mutation and selection, that mutation rates in ova and sperm are equal, and that heterozygous and homozygous normal women have the same fitness. To test this rule for Duchenne muscular dystrophy (DMD), we have examined the mothers of 55 boys with DMD (16 familial and 39 isolated cases) and classified them as carriers or noncarriers on the basis of measures of ribosomal protein synthesis (RPS). Of the 55 mothers, only nine (16.4%) are classified as noncarriers, a figure significantly different from the expected one-third. When the analysis is limited to the 39 mothers of isolated cases, 23.1% (9/39) are classified as noncarriers, still significantly different than expected under Haldane's rule. Violation of any of the assumptions under which Haldane's rule is derived could lead to deviations from the expected one-third new mutants. We find the most likely explantation to be a higher male than female mutation rate. This is supported also by the finding that maternal grandfathers in whom a mutation occurred had higher mean age at birth of the carrier daughter (33.7 +/- 1.6) than did the general population or intrapedigree controls (29.5 +/- 1.3).

Entities:  

Mesh:

Year:  1980        PMID: 7211951     DOI: 10.1002/ajmg.1320070107

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  12 in total

Review 1.  Causes, effects, and constraints in the genetics of human longevity.

Authors:  F Schächter
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

2.  On the power to detect differences between male and female mutation rates for Duchenne muscular dystrophy, using classical segregation analysis and restriction fragment length polymorphisms.

Authors:  E R Karel; G J te Meerman; L P Ten Kate
Journal:  Am J Hum Genet       Date:  1986-06       Impact factor: 11.025

3.  Sporadic cases in Duchenne muscular dystrophy. A reappraisal through segregation analysis on 988 sibships.

Authors:  A Russo; G Barbujani; M L Mostacciuolo; F H Herrmann; A W Spiegler; G Galluzzi; G A Danieli
Journal:  Hum Genet       Date:  1987-07       Impact factor: 4.132

Review 4.  Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention.

Authors:  H Moser
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

5.  Paternal age and sporadic schizophrenia: evidence for de novo mutations.

Authors:  Dolores Malaspina; Cheryl Corcoran; Cherine Fahim; Ariela Berman; Jill Harkavy-Friedman; Scott Yale; Deborah Goetz; Raymond Goetz; Susan Harlap; Jack Gorman
Journal:  Am J Med Genet       Date:  2002-04-08

6.  Duchenne muscular dystrophy. Frequency of sporadic cases.

Authors:  G A Danieli; G Barbujani
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

7.  Segregation analysis of 1885 DMD families: significant departure from the expected proportion of sporadic cases.

Authors:  G Barbujani; A Russo; G A Danieli; A W Spiegler; J Borkowska; I H Petrusewicz
Journal:  Hum Genet       Date:  1990-05       Impact factor: 4.132

8.  The genetic status of mothers of isolated cases of Duchenne muscular dystrophy.

Authors:  R J Lane; M Robinow; A D Roses
Journal:  J Med Genet       Date:  1983-02       Impact factor: 6.318

9.  Estimation of the male to female ratio of mutation rates from the segregation of X-chromosomal DNA haplotypes in Duchenne muscular dystrophy families.

Authors:  C R Müller; T Grimm
Journal:  Hum Genet       Date:  1986-10       Impact factor: 4.132

10.  Parental origin and germline mosaicism of deletions and duplications of the dystrophin gene: a European study.

Authors:  A J van Essen; S Abbs; M Baiget; E Bakker; C Boileau; C van Broeckhoven; K Bushby; A Clarke; M Claustres; A E Covone
Journal:  Hum Genet       Date:  1992-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.